ZUI-SHEN YENLai M.-S.CHEN-TI WANGChen L.-S.SHYR-CHYR CHENWEN-JONE CHENHou S.-M.2020-03-192020-03-1920040315-162Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/476621Celecoxib; Cost-benefit analysis; Hyaluronan; Naproxen; Osteoarthritis[SDGs]SDG3celecoxib; hyaluronic acid; naproxen; article; consultation; cost effectiveness analysis; drug cost; gastrointestinal symptom; health care system; health insurance; human; injection pain; knee osteoarthritis; medical specialist; priority journal; quality of life; reimbursement; Taiwan; treatment planning; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Female; Humans; Hyaluronic Acid; Middle Aged; Naproxen; Osteoarthritis, Knee; Pyrazoles; Sensitivity and Specificity; Sulfonamides; Taiwanjournal article153385032-s2.0-4444245158